Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02239094 · ClinicalTrials.gov registry record · NA

Biosignatures of Latuda for Bipolar Depression

A NA study of Bipolar Depression, sponsored by New York State Psychiatric Institute.

Completed
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT02239094 is a NA study of Bipolar Depression that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 20 participants, below the 215-participant average among 29 other Bipolar Depression trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02239094, a NA study of Bipolar Depression, has completed, sponsored by New York State Psychiatric Institute.

COMPLETED
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The study proposes to conduct a pilot study of biological predictors of lurasidone response in bipolar depression.

Conditions Studied

Interventions

  • DRUG Lurasidone (Latuda)

Study Locations (1)

New York

  • New York State Psychiatric Institute - New York

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2015-01
Est. Completion 2016-09
Phase NA

What the Registry Record Tells You About NCT02239094

The ClinicalTrials.gov registry entry for NCT02239094 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 215-participant average among 29 other Bipolar Depression trials with a reported enrollment target (91% lower). The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Bipolar Depression appearing as the primary indexed condition, and to 1 intervention - of which Lurasidone (Latuda) is the first listed.

NCT02239094 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT02239094 about?

NCT02239094 is a clinical study titled "Biosignatures of Latuda for Bipolar Depression". The study proposes to conduct a pilot study of biological predictors of lurasidone response in bipolar depression.

What is the current status of trial NCT02239094?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2015-01. Estimated completion is 2016-09.

What conditions does trial NCT02239094 study?

This clinical trial studies the following conditions: Bipolar Depression.

What interventions are being tested in trial NCT02239094?

The interventions under investigation include: Lurasidone (Latuda) (DRUG).

Who is sponsoring clinical trial NCT02239094?

This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02239094 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bipolar Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.